In this video, Dr. Douglas L. Packer of the Mayo Clinic provides details about the landmark CABANA Trial comparing Catheter Ablation to Antiarrhythmic Drugs for Atrial Fibrillation. Dr. Packer is the Lead Investigator for the CABANA Trial. Watch the video, and learn more, at: Dr. Douglas L. Packer on the CABANA Trial comparing Catheter Ablation to …
Read More
In late breaking clinical trials presented today at the American Heart Association Scientific Sessions, results of the ROCKET AF trial indicated that in an atrial fibrillation patient population that was at a very high risk of stroke, rivaroxaban (Xarelto) was as good as warfarin at preventing strokes. Learn more at: Rivaroxaban comparable to warfarin in …
Read More
New medical guidelines from the European Society of Cardiology (ESC) incorporating the latest afib research put Europe ahead of the U.S. when it comes to standardized treatment of atrial fibrillation. Stroke prevention and symptom relief are at the heart of the new ESC guidelines, which also make it clear that the risk of stroke for …
Read More
On the heels of the US FDA approving dabigatran, the long-awaited alternative to Coumadin (warfarin), comes word that Health Canada has as well. In Canada, dabigatran is known as PRADAX™. Because this is the first alternative to warfarin in Canada, it is big news for the afib community there. Learn more at: Health Canada Approves …
Read More
The long-awaited alternative to Coumadin (warfarin) has just been approved by the US FDA. The FDA just approved Pradaxa (dabigatran) for use by those with atrial fibrillation for preventing afib-related strokes. The FDA based approval on results of the RE-LY trial, which saw patients on Pradaxa having fewer strokes than those on warfarin. And Pradaxa …
Read More
An FDA panel today unanimously recommended that the FDA approve dabigatran (Pradaxa) for reducing the risk of afib strokes. FDA approval is expected quickly, making this the first alternative to warfarin approved in the United States, and also the first atrial fibrillation approval for dabigatran. It is approved in over 70 countries for venous thromboembolisms …
Read More
Next Monday, September 20, 2010, StopAfib.org will be covering the FDA's hearing on dabigatran (Pradaxa), the new alternative to warfarin, and will be "live-tweeting" from the hearing. Get first reports as they happen by following @stopafib on Twitter. If you're already on Twitter, just follow us from the toolbar at the bottom of this page. …
Read More
A new study exploring ethnic differences in stroke risk for people with atrial fibrillation (AF) showed that Mexican American stroke survivors with afib were more than twice as likely to have another stroke as comparable non-Hispanic white stroke survivors with afib. Researchers were surprised by the study’s finding that severity of recurrent stroke is also …
Read More
Atrial fibrillation took center stage in a feature story in Tuesday's Washington Post. The article not only looked at treatment for atrial fibrillation, but also at what afib does to patients. The atrial fibrillation experiences of Mellanie True Hills, founder of StopAfib.org, were included in this story. Read more at: Washington Post Highlights Afib: Atrial …
Read More
Doctors are trying to identify the characteristics that predict which patients aren’t likely to be successful with a catheter ablation for their atrial fibrillation. At a session at the recent Heart Rhythm Society annual meeting, some of the factors discussed included left atrial size, left atrial volume, left ventricle dysfunction (improper functioning of the left …
Read More